BlackRock reports 10.1% stake in Arrowhead
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BlackRock, Inc. filed an amended Schedule 13G reporting a significant ownership position in Arrowhead Pharmaceuticals Inc. common stock. BlackRock reports beneficial ownership of 14,232,545 shares, representing 10.1% of Arrowhead’s outstanding common stock.
BlackRock has sole voting power over 13,849,022 shares and sole dispositive power over 14,232,545 shares, with no shared voting or dispositive power. Various underlying clients have economic rights to dividends and sale proceeds, but no individual client holds more than five percent of Arrowhead’s outstanding common shares.
Key Figures
Key Terms
beneficially owned financial
Sole Voting Power financial
Sole Dispositive Power financial
Schedule 13G regulatory
parent holding company financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Arrowhead Pharmaceuticals (ARWR) does BlackRock currently report owning?
Does any single BlackRock client hold more than 5% of Arrowhead Pharmaceuticals (ARWR)?
What type of filing did BlackRock submit regarding Arrowhead Pharmaceuticals (ARWR)?
Who signed the BlackRock ownership report for Arrowhead Pharmaceuticals (ARWR)?
AI-generated analysis. How Rhea-AI works. Not financial advice.